Identifying calcineurin activators for treatment of schizophrenia
View Patent ↗The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.
1. A method for identifying a candidate compound for treatment of schizophrenia comprising steps of
performing an assay to identify a calcineurin activator; and
testing the calcineurin activator in at least one schizophrenia disease model to determine if the calcineurin activator ameliorates at least one symptom in the schizophrenia disease model.
2. The method of claim 1 , further comprising the steps of modifying the calcineurin activator and testing the modified calcineurin activator to select a modified calcineurin activator that has increased solubility, absorbability or bioavailability as compared to the calcineurin activator prior to modification.
3. The method of claim 1 , further comprising the steps of modifying the calcineurin activator and testing the modified calcineurin activator to select a modified calcineurin activator that has enhanced ability to cross the blood-brain barrier as compared to the calcineurin activator prior to modification.
4. The method of claim 1 , wherein the step of performing an assay comprises:
providing a biological system comprising phosphorylated calcineurin substrate and calcineurin;
contacting the biological system with a compound;
comparing the extent or rate of dephosphorylation of the substrate with the extent or rate of dephosphorylation occurring in the absence of the compound; and
identifying the compound as a candidate compound that increases calcineurin activity if the extent or rate of dephosphorylation in the presence of the compound is increased compared to the extent or rate of dephosphorylation that occurs in the absence of the compound.
5. The method of claim 1 , further comprising a step of testing the candidate compound in a human subject suffering from schizophrenia.